COVID-19 associated liver injury: An updated review on the mechanisms and management of risk groups

Shi, Yifan; Wang, Mina; Wu, Liqun; Li, Xuexin; Liao, Ziqi

doi:10.1016/j.livres.2023.07.001

Cited by 5 publications

(4 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As aforementioned, cancer and infectious diseases are the two most common challenges humankind is faced with currently, despite multiple in‐progress research and treatment measures, satisfactory results are yet to be achieved. The emergence of new pandemics like COVID‐19, Ebola, Zika, HIV and measles has necessitated the need for finding a new approach or new technique unlike before to overcome the crisis in healthcare and for the betterment of human life 43–46 . A dormant technique that was considered almost impossible to be implemented in the 19th century was ventured again in the last decade and reinstalled confidence in the form of nucleic acid encoded therapeutics.…”

Section: Mrna Cancer Vaccines: History and Recent Advancesmentioning

confidence: 99%

“…The emergence of new pandemics like COVID-19, Ebola, Zika, HIV and measles has necessitated the need for finding a new approach or new technique unlike before to overcome the crisis in healthcare and for the betterment of human life. [43][44][45][46] A dormant technique that was considered almost impossible to be implemented in the 19th century was ventured again in the last decade and reinstalled confidence in the form of nucleic acid encoded therapeutics. Recent advances in research have given us deeper knowledge of human genetics and have created an avenue for mRNA as a promising treatment protocol for infectious diseases and cancer.…”

Section: Mrna Cancer Vaccines: History and Recent Advancesmentioning

confidence: 99%

See 1 more Smart Citation

mRNA vaccine in cancer therapy: Current advance and future outlook

Li,

Wang,

Peng

et al. 2023

Clinical & Translational Med

Self Cite

View full text Add to dashboard Cite

Messenger ribonucleic acid (mRNA) vaccines are a relatively new class of vaccines that have shown great promise in the immunotherapy of a wide variety of infectious diseases and cancer. In the past 2 years, SARS‐CoV‐2 mRNA vaccines have contributed tremendously against SARS‐CoV2, which has prompted the arrival of the mRNA vaccine research boom, especially in the research of cancer vaccines. Compared with conventional cancer vaccines, mRNA vaccines have significant advantages, including efficient production of protective immune responses, relatively low side effects and lower cost of acquisition. In this review, we elaborated on the development of cancer vaccines and mRNA cancer vaccines, as well as the potential biological mechanisms of mRNA cancer vaccines and the latest progress in various tumour treatments, and discussed the challenges and future directions for the field.

show abstract

Section: Mrna Cancer Vaccines: History and Recent Advancesmentioning

confidence: 99%

Section: Mrna Cancer Vaccines: History and Recent Advancesmentioning

confidence: 99%

mRNA vaccine in cancer therapy: Current advance and future outlook

Li,

Wang,

Peng

et al. 2023

Clinical & Translational Med

Self Cite

View full text Add to dashboard Cite

show abstract

“…Coronavirus disease 2019 (COVID- 19) is an extremely infectious respiratory disorder caused by the novel coronavirus SARS-CoV-2. (1,2) It has resulted in a global pandemic characterized by a wide spec-trum of symptoms, from moderate respiratory issues to severe pneumonia.…”

Section: Introductionmentioning

confidence: 99%

“…(18) Moreover, the inflammation and blood clotting issues in severe COVID-19 can worsen liver damage in those with existing liver conditions. (19,20) This cross-sectional study at Sohag University Hospital investigates the impact of COVID-19 on individuals with Chronic Liver Disease, encompassing the assessment of complete blood picture (CBC), liver enzymes, and inflammatory markers.…”

Section: Introductionmentioning

confidence: 99%

Impact of COVID-19 infection on patients with chronic liver disease in Sohag University Hospital.

Hussein Mohammed,

Younis,

Zaghloul

2024

Sohag Medical Journal

View full text Add to dashboard Cite

The pandemic of the coronavirus disease 2019 (COVID-19) has significantly impacted global public health and presented diverse clinical symptoms. Liver involvement in COVID-19 is notable, affecting a significant proportion of patients. Methods: A retrospective cross-sectional study was conducted at Sohag University Hospital. A comparative analysis between chronic liver disease (CLD) patients with and without COVID-19. The study employed logistic regression and receiver operating characteristic (ROC) curve analysis to explore predictors of COVID-19 severity in CLD patients. Results: 272 participants were included: 66 in the control group and 206 with varying COVID-19 severity. White blood cell count (WBC) was notably higher in severe cases compared to mild ,moderate and the control group . Absolute lymphocytic count also displayed significant differences, with the control group having higher values (2.25 ± 0.73) compared to mild (1.9 ± 0.86), moderate (1.27 ± 0.52), and severe cases (1.3 ± 0.78). Furthermore, C-reactive protein (CRP) varied significantly, with the highest levels in severe cases (92.9 ± 46), followed by moderate cases (46.7 ± 40.2), mild cases (13.49 ± 19.5), and the control group (5.6 ± 1.9). Elevated CRP (P = 0.001) with a sensitivity of 98%, D-dimer (P = 0.008) with a sensitivity of 95.7%, ESR (P = 0.008) with a sensitivity of 78.7%, and LDH (P = 0.013) with a sensitivity of 72.3% were significantly associated and predicted increased COVID-19 severity. Conclusion: This research enhances understanding of COVID-19's impact on individuals with CLD, highlighting the significance of CRP, D-dimer, ESR, and LDH as a predictors of severity.

show abstract